NICE recommends Roche’s Tecentriq in ES-SCLC following price rethinkNICE has said that Roche’s Tecentriq (atezolizumab) plus chemotherapy should be funded by the NHS as an option for untreated extensive-stage small-cell Share XNICE recommends Roche’s Tecentriq in ES-SCLC following price rethinkhttps://pharmaphorum.com/news/nice-recommends-roches-tecentriq-in-es-sclc-following-price-rethink/
